Treatment of Type 2 Diabetes Mellitus in Advanced Chronic Kidney Disease for the Primary Care Physician
- PMID: 39149651
- PMCID: PMC11326530
- DOI: 10.7759/cureus.64663
Treatment of Type 2 Diabetes Mellitus in Advanced Chronic Kidney Disease for the Primary Care Physician
Abstract
Diabetes mellitus (DM) is a common cause of chronic kidney disease (CKD), leading to the need for renal replacement therapy (RRT). RRT includes hemodialysis (HD), peritoneal dialysis (PD), kidney transplantation (KT), and medical management. As CKD advances, the management of DM may change as medication clearance, effectiveness, and side effects can be altered due to decreasing renal clearance. Medications like metformin that were safe to use early in CKD may build up toxic levels of metabolites in advanced CKD. Other medications, like sodium-glucose co-transporter 2 inhibitors, which work by excreting glucose in the urine, may not be able to work effectively in advanced CKD due to fewer working nephrons. Insulin breakdown may take longer, and both formulation and dosing may need to be changed to avoid hypoglycemia. While DM control contributes to CKD progression, effective DM control continues to be important even after patients have been placed on RRT. Patients on RRT are frequently taken care of by a team of providers, including the primary care physician, both in and outside the hospital. Non-nephrologists who are involved with the care of a patient treated with RRT need to be adept at managing DM in this population. This paper aims to outline the management of type 2 DM in advanced CKD.
Keywords: chronic kidney disease; end stage renal disease; hd ( hemodialysis ); insulin regimen; kidney transplantation; peritoneal dialysis; sglt2-inhibitors; type 2 diabetes mellitus.
Copyright © 2024, Mallappallil et al.
Conflict of interest statement
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
References
-
- The effect of diabetes on incidence and mortality in end-stage renal disease in Germany. Hoffmann F, Haastert B, Koch M, Giani G, Glaeske G, Icks A. Nephrol Dial Transplant. 2011;26:1634–1640. - PubMed
-
- Top 10 Predictions about US Nephrologists in 2035. ASN Executive Vice President's Update. [ Jul; 2024 ]. 2022. https://www.kidneynews.org/view/journals/kidney-news/14/7/article-p8_3.xml https://www.kidneynews.org/view/journals/kidney-news/14/7/article-p8_3.xml
-
- USRDS: 2022 USRDS Annual Data Report. USRDS: 2022 USRDS Annual Data Report. [ Jun; 2024 ]. 2022. https://usrds-adr.niddk.nih.gov/2022/introduction https://usrds-adr.niddk.nih.gov/2022/introduction
Publication types
LinkOut - more resources
Full Text Sources
Research Materials